Physician profile
Ahmad Daif
NPI 1326459553
$3,608.65
in general payments reported to CMS, 2019-2025
35 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2021: $107 · 2023: $150 · 2024: $1,373 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227 · Education: $81.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.73 |
| Education | $81.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $450.89 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $289.82 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $282.48 | 2024-2025 | Valtoco |
| Abbvie INC. | $254.40 | 2024-2025 | |
| Ucb, INC. | $200.81 | 2025 | Fintepla, Nayzilam, Rystiggo |
| Janssen Biotech, INC. | $190.54 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $169.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.99 | 2023-2025 | Entyvio |
| Argenx US, INC. | $147.23 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $138.23 | 2023-2025 | Zeposia |
| Genentech USA, INC. | $133.33 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $125.91 | 2024-2025 | |
| Amgen INC. | $124.08 | 2021-2024 | Tavneos |
| Travere Therapeutics, INC. | $115.22 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.07 | 2024-2025 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $73.81 | 2024-2025 | Vyepti, Rexulti |
| Livanova USA, INC. | $59.11 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Phathom Pharmaceuticals, INC. | $57.02 | 2024 | Voquezna |
| Lilly USA, LLC | $56.46 | 2025 | Kisunla, Amyvid |
| Abbott Laboratories | $54.53 | 2025 | Infinity |
| Acadia Pharmaceuticals INC | $52.97 | 2025 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.63 | 2024-2025 | Rexulti |
| Pfizer INC. | $42.24 | 2025 | |
| Alexion Pharmaceuticals, INC. | $38.99 | 2019 | |
| Alnylam Pharmaceuticals INC. | $32.50 | 2024 | Onpattro |
| Organon LLC | $27.95 | 2023 | Hadlima |
| E.R. Squibb & Sons, L.L.C. | $26.95 | 2024 | Camzyos |
| Averitas Pharma INC. | $24.21 | 2025 | Qutenza |
| Ceribell, INC. | $22.14 | 2024 | Pocket Eeg Device |
| Ani Pharmaceuticals, INC. | $22.02 | 2023 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $21.78 | 2024 | Watchman Flx |
| Vertex Pharmaceuticals Incorporated | $21.62 | 2025 | |
| Merck Sharp & Dohme LLC | $19.92 | 2023 | Dificid |
| Harmony Biosciences LLC | $16.40 | 2024 | |
| Allergan, INC. | $14.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Daif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.